Anna Protopapas

2020

In 2020, Anna Protopapas earned a total compensation of $2.5M as President and Chief Executive Officer at Mersana Therapeutics, a 46% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$324,500
Option Awards$1,220,079
Salary$550,000
Stock Awards$436,331
Other$7,000
Total$2,537,911

Protopapas received $1.2M in option awards, accounting for 48% of the total pay in 2020.

Protopapas also received $324.5K in non-equity incentive plan, $550K in salary, $436.3K in stock awards and $7K in other compensation.

Rankings

In 2020, Anna Protopapas' compensation ranked 4,481st out of 13,090 executives tracked by ExecPay. In other words, Protopapas earned more than 65.8% of executives.

ClassificationRankingPercentile
All
4,481
out of 13,090
66th
Division
Manufacturing
1,815
out of 5,618
68th
Major group
Chemicals And Allied Products
703
out of 2,251
69th
Industry group
Drugs
602
out of 1,951
69th
Industry
Pharmaceutical Preparations
457
out of 1,456
69th
Source: SEC filing on April 27, 2021.

Protopapas' colleagues

We found four more compensation records of executives who worked with Anna Protopapas at Mersana Therapeutics in 2020.

2020

Arvin Yang

Mersana Therapeutics

Chief Medical Officer

2020

Timothy Lowinger

Mersana Therapeutics

Chief Science and Technology Officer

2020

Michael Kaufman

Mersana Therapeutics

Chief Manufacturing Officer

2020

Brian DeSchuytner

Mersana Therapeutics

Senior Vice President, Finance & Product Strategy

News

You may also like